Nitric oxide (NO) exerts a wide range of cellular effects in the cardiovascular system. NO is 43 short-lived, but S-nitrosoglutathione (GSNO) functions as a stable intracellular bioavailable NO 44 pool. Accordingly, increased levels can facilitate NO-mediated processes, and conversely, 45 catabolism of GSNO by the regulatory enzyme GSNO reductase (GSNOR) can impair these 46 processes. Because dysregulated GSNOR can interfere with processes relevant to cardiovascular 47 health, it follows that inhibition of GSNOR may be beneficial. However, the effect of GSNOR 48 inhibition on vascular activity is unknown. To study the effects of GSNOR inhibition on 49 endothelial function, we treated rats with a small-molecule inhibitor of GSNOR (N6338) initially impaired state (7.4±1.7% day 0) to a level (13.0±3.1% day 14, P<0.001) similar to that 58 observed in normotensive rats. N6338 also reversed the pathological kidney changes exhibited 59 by the hypertensive rats. GSNOR inhibition preserves FMD under conditions of impaired NO 60 production and protects against both microvascular and conduit artery dysfunction in a model of 61 hypertension. 62 KEYWORDS-hypertension, flow-mediated vasodilation, nitric oxide, S-nitrosoglutathione, S-63 nitrosoglutathione reductase
Nitric oxide (NO) has emerged as a key player in the cardiovascular system, mediating diverse 65 physiological processes including vasodilation (31, 33, 41) . Many effects of NO are mediated by 66 the transfer of an NO group to cysteine sulfhydryls on proteins via S-nitrosylation (35), a process 67 that plays an important role in many NO-dependent cardiovascular processes (20) and causes 68 significant protein modification within endothelial cells (43) . NO is short-lived, but exists 69 physiologically in other forms like nitrite, nitrate, and S-nitrosothiols (SNOs), which include S-70 nitrosylated cysteine residues in serum proteins, and S-nitrosoglutathione (GSNO) in the 71 cytoplasm. In particular, GSNO is thought to serve as an important intracellular bioavailable NO 72 pool, which is in equilibrium with other intracellular SNOs that facilitate transnitrosylation (NO 73 transfer between proteins) (12, 18) . Accordingly, increased levels of GSNO can facilitate NO-74 mediated processes, and conversely, catabolism of GSNO by GSNO reductase (GSNOR), a 75 regulatory enzyme that degrades GSNO and is thought to be the main regulator of GSNO levels 76 in vivo (22), can impair these processes. This premise is supported by the observations that in 77 human asthma, GSNOR regulates airway SNO content and hyperresponsiveness (29, 30) , and 78 GSNOR-deficient mice are protected from airway hyperresponsiveness in an asthma model (28) . 79
Because dysregulated GSNOR can reduce levels of GSNO and can interfere with processes 80 relevant to cardiovascular health, it follows that GSNOR inhibition may be beneficial in certain 81 situations. GSNOR inhibition promotes vasorelaxation of isolated aortic rings (32) and genetic 82 deletion of GSNOR lowers systemic vascular resistance and improves post-infarction myocardial 83 perfusion (21, 23), although complete deletion also lowers cardiac contractility (4). Together, 84 these observations suggest that GSNOR is highly relevant to the cardiovascular system and that 85 inhibition under appropriate circumstances could provide therapeutic strategies for various forms 86 of cardiovascular disease. 87 GSNOR, 240 µM GSNO, and 300 µM NADH in 100 mM sodium phosphate buffer, pH 7.4 at 134 25˚C. N6338 concentrations ranged from 0-2 µM. Reaction volumes were 300 µL in a UV 135 transparent 96-well plate (Costar 3635). The change in absorbance at 340 nm (from oxidation of 136 NADH to NAD + ) was followed for 3 min in a SpectraMax M2 plate reader. The initial linear 137 reaction rate (mAU 340 /min) was plotted against inhibitor concentration and fit to a sigmoidal 138 dose-response model (variable slope) using GraphPad Prism 5 software. 139
140

GSNOR immunohistochemistry 141
Formalin fixed, paraffin embedded tissues from Dahl-S study rats (normal diet vehicle control 142 group) were stained with a rabbit polyclonal GSNOR antibody (11051-1-AP, Proteintech, 143
Chicago, IL). Commercially available human tissues (tissue source for Figure 1C ,D from 144
Premier Laboratories, Longmont, CO; for 1E from Folio Biosciences, Columbus, OH) were 145 stained with a monoclonal anti-GSNOR antibody (N30-C3) raised in a rat immunized with full 146 length human GSNOR protein at ProMab Biotechnologies (Richmond, CA) for N30 147
Pharmaceuticals. Slides were deparaffinized in xylene and rehydrated to water though a series of 148 alcohol gradients. The slides were pretreated in a 95˚C citrate pH 6.1 antigenic retrieval solution 149 (Dako, Carpinteria, CA) . After allowing the slides to cool to room temperature, a 3% hydrogen 150 peroxide solution (EMD Chemicals, Gibbstown, NJ) was added to quench endogenous 151 peroxidase activity. Slides were preincubated with Serum Free Protein Block (Dako), followed 152 by incubation with the GSNOR antibody or a non-specific rat IgG control (AbD Serotec, 153 Raleigh, NC) or rabbit Ig fraction (Dako). Human tissue slides were then incubated with rabbit 154 anti rat immunoglobulin (Dako), and both human and rat tissues were labeled with a goat anti7 rabbit polymer (Dako). DAB+ (Dako) was used for detection and slides were counter-stained 156 with hematoxylin (Dako). 157
158
GSNOR activity 159
Hearts and aortas from male Sprague-Dawley rats (Harlan, Indianapolis, IN, 8-10 weeks of age, 160 weighing 250-300 g) were frozen in liquid nitrogen and stored at -70˚C. Tissues were pulverized 161 to powder in liquid nitrogen and then homogenized in 50 mM Tris-HCl (pH 7.4), 250 mM NaCl, 162 0.1 mM DTPA, 10 mM NEM, 1% igepal CA-630, with complete, EDTA-free, protease inhibitor 163 cocktail (Roche Diagnostics, Mannheim, Germany). Homogenates were clarified by 164 centrifugation and total protein determined by the bicinchoninic acid method. Tissue 165 homogenates (4.4 mg/mL total protein) were diluted 10-fold into reaction buffer (100 mM 166 sodium phosphate pH 7.4 and 250 µM NADH). GSNO-dependent NADH depletion was 167 determined spectrophotometrically by measuring change in absorbance at 340 nm for 3 min at 168 20˚C in the absence and presence of 250 µM GSNO. Additions of N6338 to reactions containing 169 GSNO were as indicated in the text. 170
171
Measurement of nitrosated species (SNOs) 172
Mouse embryonic fibroblast cells (a generous gift from Limin Liu, UCSF) were immortalized 173 with SV-40 T-antigen (Applied Biological Materials, Richmond, BC, Canada). The cells were 174 cultured in 6-well plates at 1-2x10 6 cells/well and grown overnight in DMEM supplemented with 175 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM glutamine. Media was 176 replaced with fresh DMEM with 500 µM GSNO (N30 Pharmaceuticals) and either vehicle or 50 177 µM N6338 and incubated for 4 hours. Nitrosylated species were quantitated using the triiodide8 based chemiluminescence method as described (32) flow velocity (V). V was calculated as velocity-time integral x duration of heart cycle. All 216 diameter readings were taken at diastole, and flow velocity represents the mean angle-corrected 217 Doppler-flow velocity. FMD was calculated as % change: (peak diameter postischemia -218 diameter baseline )/ diameter baseline x 100, and presented both as raw data and indexed to wall shear 219 rate (WSR) by calculating FMD/WSR. WSR was calculated as 4 x velocity/diameter at peak 220 response. We used WSR rather than wall shear stress, which also depends on blood viscosity, 221 under the assumption that blood viscosity was constant. For aortic ring relaxation, statistical analysis was performed using GraphPad Prism and 244 significant differences among groups were determined via two-way ANOVA with treatment and 245 dose as factors, followed by Bonferroni's post-hoc correction for multiple comparisons. 246
Statistical analysis was performed using one-way ANOVA for weight comparisons, two-wayANOVA for aortic ring relaxation measurement, and two-way repeated measures ANOVA for 248 the acute FMD suppression study and for BP and FMD comparison in the chronic study with 249 GraphPad Prism, followed by Bonferroni post hoc correction with significance adjusted for 250 multiple comparisons where appropriate. Single comparison between all untreated (day 0) Dahl-251 S rats on high salt vs. low salt in the chronic study was performed by Student's t-test. For 252 vascular resistance index, a two-way repeated measures ANOVA was performed with main 253 factors salt level and treatment, and planned pairwise comparisons were tested using linear 254 contrast statements with significance determined using Bonferroni adjustment for multiple 255 comparisons. Analyses were performed using Statistica (v6.0, StatSoft, Inc). Statistical 256 significance was determined after adjusting for multiple comparisons to maintain the overall 257 alpha error rate of P<0.05. 258
259
RESULTS
260
N6338 is a GSNOR inhibitor 261
N6338 caused dose-dependent, potent inhibition of human GSNOR activity in vitro ( Figure 1A of GSNOR in small macrovessels in human and rat heart tissue sections. In both species, 268 arterioles and presumably small arteries showed prominent GSNOR immunostaining in smooth 269 muscle, but little, if any, staining in endothelium ( Figure 1D, G) . In a human venule, GSNORstaining was apparent in endothelium ( Figure 1E ). GSNOR was also prominently expressed in 271 human cardiomyocytes ( Figure 1E ). Consistent with the results in human tissue, faint staining 272 was observed in rat cardiomyocytes ( Figure 1G ). No staining was evident in human ( Figure 1C ) 273 or rat ( Figure 1F ) heart sections stained with the respective IgG negative control. 274 275 GSNOR activity in cardiovascular tissues 276 GSNOR enzyme activity was measured in rat heart and aorta homogenates to further identify the 277 presence of GSNOR in vascular tissue. GSNOR activity was detected in homogenates from both 278 rat aorta and heart ( Figure 1H ). N6338 inhibited this enzyme activity when added in vitro. 279
Specifically, N6338 decreased GSNOR activity by 73.3 ± 8.5% (heart) and 85.3 ± 17.7% (aorta) 280 at 1 µM N6338, and by 90.8 ± 1.5% (heart) and 94.5 ± 6. 2% (aorta) at 10 µM N6338. 281
282
N6338 causes relaxation of preconstricted aortic rings in vitro 283
To further demonstrate that GSNOR inhibition by N6338 can directly influence vascular tone, 284
the effects of N6338 were tested in isolated aortic rings. N6338 caused a dose-dependent 285 relaxation in rat aortic rings that had been precontracted with phenylephrine ( Figure 1I ). To 286 determine whether this relaxation was NO-dependent, reagents affecting various pathways of 287 NO-mediated relaxation were added prior to the phenylephrine and N6338 additions. Incubation 288 of rings with either soluble guanylate cyclase inhibitor ODQ, NOS inhibitor L-NMMA, or NO 289 scavenger carboxy PTIO significantly attenuated N6338 (1 to 100 μM) relaxation compared to 290 vehicle-treated control rings, demonstrating the dependence of N6338's effects on the classical 291 NO/cGMP mechanism for smooth muscle relaxation. 292
GSNOR inhibition prevented impairment of FMD caused by partial inhibition of eNOS 294
We first determined whether a single dose of GSNOR inhibitor could preserve FMD under 295 conditions of partial NOS inhibition. Rats were injected i.v. with PBS (negative control) or 296 N6338 (10 mg/kg in 0.1 ml saline/100 g) followed by 300 µl PBS to flush the infusion system. 297
After 24 hours, we measured FMD and then administered 5 mg/kg of the NOS inhibitor L-298 NMMA, a dose that we had previously determined to inhibit FMD by approximately 50% (Q.C., 299 unpublished). FMD was measured again 10 min after L-NMMA. We used a cross-over design in 300 which rats were randomly split into two groups (n=7/group), with one group given N6338 and 301 the other group given PBS. After a 2 week wash-out period, the groups were reversed and 302 received the opposite treatment. As shown in Figure 2 , FMD responses 24 h after treatment with 303 PBS or N6338, but before L-NMMA, were similar, indicating that GSNOR inhibition has little 304 or no effect on FMD in normal arteries. However, while L-NMMA significantly reduced FMD in 305 PBS-treated rats (14.1±2.9% vs. 7.6±4.4%, P<0.05), there was no significant difference in FMD 306 before and after L-NMMA in N6338-treated rats (15.3±5.4% vs. 14.2±6.3%, P=NS). There was 307 also a significant difference between post-L-NMMA FMD in the PBS-treated vs. N6338-treated 308 rats (7.6±4.4% vs. 14.2±6.3%, P<0.05). Calculation of FMD relative to WSR (FMD indexed to 309 WSR) resulted in similar relationships. Femoral artery diameter was not significantly decreased 310 by L-NMMA before or after occlusion in each group (data not shown). These results 311 demonstrate that N6338 prevented the reduction in FMD that would have otherwise occurred 312 following administration of L-NMMA. 313
314
GSNOR inhibition reduced BP in Dahl-S hypertensive rats 315
We then asked if it is possible to recapitulate decreased FMD in an inflammation-based chronichypertension model, the Dahl-S rat maintained on a high-salt diet, and whether inhibition of 317 GSNOR could reduce BP and restore FMD in this model. N6338 in a solubilization vehicle 318 (0.5% wt/vol carboxymethylcellulose) was delivered orally at 10 mg/kg/day once daily, 319 beginning at day 0; control groups received only vehicle. Hypertensive and normotensive rats 320 had been previously randomized to groups after the initial BP measurement. 321
As shown in Figure 3A and with exact values shown in Table 1 resulting from tail cuff measurements are approximations based on the systolic measurements, 326 but are presented for reference.) BP in the high-salt vehicle group was substantially higher than 327 BP in the low-salt groups (p<0.05 overall), confirming that this rat model of vascular disease 328 successfully manifested a disease state similar to that of hypertensive humans. 329
While the overall F-test was significant, specific inter-group comparisons failed to retain 330 significance after adjusting the alpha error rate for multiple comparisons in the anesthetized 331 animals. For this reason, and because anesthetized conditions result in abnormally low BP 332 especially as measured with tail cuff methodology, we performed a similar experiment in which 333 BP was measured in conscious Dahl-S rats acclimated to the procedure with exact values shown 334 in Table 2 . Notably, in the high-salt drug group, BP was initially high, but decreased 335 significantly over time and was substantially lower by D9 and D14; demonstrating a BP-336 lowering effect of the GSNOR inhibitor in hypertensive, but not normotensive, Dahl-S rats 337 ( Figure 3B ). (The subsequent results presented below derive from the rats in which BP had been 338 measured under anesthesia.) 339
GSNOR inhibition reduced vascular resistance in Dahl-S hypertensive rats 341
Measuring vascular resistance provides a more reliable indication of microvascular tone than 342 assessing BP alone. To determine if GSNOR inhibition protects microvascular function in Dahl-343 S hypertensive rats, we calculated a vascular resistance index using the systolic BP 344 measurements and the diastolic BP approximations (see Methods) at both baseline (i.e., prior to 345 femoral artery occlusion) and at peak blood flow during reactive hyperemia. This provides an 346 indication of the extent to which chronic GSNOR inhibition impacts microvascular tone at "rest" 347 and under near maximal dilatory conditions in a disease state with increased microvascular 348 resistance. 349
As shown in Figure 4 
GSNOR inhibition restored FMD of Dahl-S hypertensive rats to the level of normotensive rats 367
To assess the effects of GSNOR inhibition on endothelial function in the hypertensive rats, FMD 368 was measured at D0, D1, and D14 ( Figure 5 ). The coefficient of variation for the low-salt vehicle 369 group over time (calculated for individual rats over time and averaged) was 0.207. Similar to the 370 BP results described above, FMD was normal in both low-salt groups, and impaired in the high-371 salt vehicle group (13.9±3.3% and 13.1±4.4% vs. 7.6±3.0%, P<0.05). Pairwise differences 372 between groups on any given day did not reach significance, but FMD of all high-salt rats was 373 significantly lower than that of all low-salt rats on D0, before treatment commenced (p=0.0027), 374 confirming that FMD is impaired in Dahl-S rats on a high-salt diet. While GSNOR inhibitor 375 treatment had no effect on FMD in the low-salt groups, it progressively and completely restored 376 FMD to normal levels in the high-salt group between D0 and D14 (7.4±1.7% vs. 13.0±3.1%, 377 P<0.001). No significant difference was observed between femoral artery basal diameters in the 378 N6338 and vehicle high-salt groups (not shown). Furthermore, there were no differences in 379 either aorta cGMP or plasma nitrite levels between N6338 and vehicle high-salt groups (not 380 shown). Indexing of FMD to WSR reduced the level of significance but preserved the main 381 effect, confirming that despite the functional defect in the microvasculature of the high-salt rats 382 and its reversal by GSNOR inhibition, the conduit artery response to hyperemia was similarly 383 impaired in the high-salt groups and reversed by GSNOR inhibition. 384
GSNOR inhibition prevented renal damage observed in hypertensive rats 386
At the end of the experiment, the rats were euthanized and the heart and kidneys from each rat 387 were weighed. As shown in Fig. 6A , kidney weights were increased in the high-salt vehicle 388 group (3.3±0.3 g) compared to weights in both low-salt groups (2.7±0.1 g and 2.6±0.2 g, 389 P<0.001). GSNOR inhibition caused a trend toward lower kidney weights (2.9±0.3 g in the high-390 salt drug group vs. 3.3±0.3 g in the high-salt vehicle group, P<0.05). In contrast, there were no 391 significant differences in heart weights (Fig. 6B ) or body weights (not shown) among groups. 392
Histological assessment of kidneys showed that both low-salt groups had kidneys with 393 normal glomerular and tubular architecture (Fig. 6C,D) . Kidneys of high-salt rats showed 394 significant tubular defects, whereas the glomeruli were mostly unaffected. All of these 395 pathological conditions were substantially reduced in rats treated with N6338 as compared with 396 vehicle (Fig. 6E,F) , demonstrating that reversal of the pathological consequences of the Dahl-S 397 hypertensive rat model by GSNOR inhibition was not limited to the cardiovascular system. 398
399
DISCUSSION 400
This study shows that the GSNOR inhibitor, N6338, preserves FMD under partial NOS 401 inhibition, reduces BP and vascular resistance in hypertensive rats, and restores FMD in 402 hypertensive rats from a substantially impaired state to that of normotensive rats. These results 403 suggest that N6338 protects against both microvascular and conduit artery vasoactive 404 dysfunction in a model of vascular inflammation and hypertension (27, 46) , and that GSNOR 405 inhibition may provide a strategy to increase bioavailable NO as a therapy for a number of 406 vascular disorders (19). As NO has typically been linked to endothelial function through eNOS 407 activity (e.g. FMD and eNOS are both impaired by cigarette smoke exposure in humans (3) It is not clear why acutely depressed FMD, a process that requires active synthesis of NO by 419 eNOS, was improved by N6338, which likely increased levels of pre-existing stores of NO. It is 420 possible that under normal conditions, some of the NO generated acutely during reactive 421 hyperemia is immediately consumed by processes other than those directly involved with 422 relaxation of the affected artery. The FMD normally observed, therefore, may reflect the effect 423 of residual acutely-generated NO. Because bioavailable NO is in equilibrium with both short-424 term NO-consuming processes and NO storage pools, including GSNO, increasing basal GSNO 425 levels prior to eliciting FMD may pre-load the normal NO sinks that would otherwise consume 426 NO generated acutely in response to reactive hyperemia. Hence, a higher net level of 427 bioavailable NO may result during reactive hyperemia in the face of GSNOR inhibition than 428 during normal GSNOR activity. The fact that N6338 did not increase FMD in the absence of L-429 NMMA may indicate that the NO pulse normally elicited by reactive hyperemia in our protocol 430 elicits maximal artery dilation and further increasing bioavailable NO via GSNOR inhibition has 431 no effect. By contrast, the L-NMMA dose selected for our acute rat studies depressed hyperemia-432 induced NO below the level required to generate a maximal dilation response. Under this 433 condition, GSNOR inhibition may increase bioavailable NO sufficiently to fully restore FMD 434 despite co-existing partial inhibition of eNOS, as was observed. Our observation that L-NMMA 435 inhibited the N6338-induced relaxation of pre-constricted aortic rings at only the lower N6338 436 concentrations tested further supports the importance of the stoichiometry between acutely-437 produced NO and the bioavailable NO pool. It is also notable that we observed substantial 438 presence of GSNOR in the smooth muscle of arterioles and small arteries, suggesting that 439 downstream elevation of bioavailable NO directly in the smooth muscle of arteries by GSNOR 440 inhibition may compensate for possibly lower upstream production of NO by the endothelium. 441
Of perhaps greater importance is the observation that a probable chronic elevation of 442 bioavailable NO, secondary to GSNOR inhibition, restores the magnitude of FMD in the Dahl-S 443 hypertensive rat. This finding is consistent with reports that eNOS expression and endothelial-444 dependent relaxation are impaired in conduit arteries isolated from hypertensive Dahl-S rats (27, 445 45). Arterial β-adrenergic responsiveness is also decreased (34). Moreover, the high-salt diet 446 may impair FMD directly, as even in healthy humans, a high-salt meal has been shown to reduce 447 FMD in 30 minutes (10). Thus, FMD in hypertensive Dahl-S rats may be disrupted via intrinsic 448 defects in conduit artery endothelial signaling that would otherwise lead to smooth muscle 449 relaxation. 450
Sub-chronic GSNOR inhibition decreased femoral artery vascular resistance in high-salt 451
Dahl-S rats compared to resistance in vehicle control high-salt rats under baseline conditions 452 (pre-occlusion) and during reactive hyperemia (post-occlusion). Both of these observations have 453 clinical relevance. Baseline vascular resistance primarily reflects basal microvascular tone, aunpublished). Thus, prevention of kidney weight increase and damage by N6338 may be 478 attributable, at least partly, to anti-inflammatory activity. Notably, moderately-old eNOS knock-479 out mice suffer from hypertension and renal injury that are exacerbated by high-salt diet (9), 480 underscoring the connection between bioavailable NO and the control of these conditions. 481
It has recently been reported that complete absence of GSNOR in knock-out mice results in 482 deficient DNA repair and increased propensity for tumorigenesis (25, 42) . While there is a 483 substantial difference between pharmacological inhibition of an enzyme and the life-long total 484 absence of the protein, these results should be taken into consideration in the planning of initial 485 clinical studies to ensure that such effects are prevented at the dosage used. 486
A limitation of this study is that the direct detection of N6338-induced changes in GSNOR 487 activity in vivo is impractical because N6338 reversibly inhibits GSNOR. Therefore, disruption 488 of tissues destroys the microenvironment within the cell and dilutes cellular contents, resulting in 489 substantial dissociation of the inhibitor and restoration of enzymatic activity. Furthermore, direct 490 measurement of endogenous GSNO levels is challenging and generally below levels of detection 491 by current methods. However, GSNOR knock-out mice have demonstrated increased 492 bioavailable NO as measured by heme-bound NO (22) . By addition of GSNO to a cell-based 493 SNO assay to increase SNO levels to within detectable range, we confirmed that N6338 494 increases SNOs in cultured cells, implicating GSNO preservation as a primary mechanism of 495 N6338's effects in a biological system. Taken together, the in vivo effects of treatment with 496 GSNOR inhibitor N6338, paired with evidence of GSNOR inhibition from our in vitro 497 experiments, strongly suggest that GSNOR inhibition led to an increase in NO-mediated 498 signaling that cumulatively improved cardiovascular hemodynamics and renal pathology in this 499 study. 500
In summary, using an approach that we developed to measure FMD in living rats, we have 501
shown heart, and (E) predominantly in the endothelium of a human myocardial venule; (F) IgG negative 666 control or (G) rat-specific GSNOR antibody staining predominantly in the smooth muscle of an 667 arteriole in rat heart. In all micrographs, scale bars = 50 µm, asterisks denote vessel lumens, blue 668 arrows show smooth muscle, and red arrows show endothelium. (H) GSNOR activity was 669 present in rat heart and aorta, and inhibited by N6338 when this compound was added in vitro. impaired in the hypertensive rats. N6338 fully restored FMD over the two-week treatment period 698 to levels seen in normotensive control rats. FMD is shown both as raw data and indexed to WSR. 699
The comparisons between individual groups did not reach significance, although significance 700 was reached for the overall effect with p<0.05. The difference in FMD in all high-salt rats vs. all 701 low-salt rats at D0 was significant (p=0.0027, t-test). The change from D0 to D14 in the high-salt 
